AMX0114 is an antisense oligonucleotide made to prevent or slow the degeneration of axons, which is a key driver of ALS ...

The first ALS patient has been enrolled in an NIH-funded expanded access program trial evaluating MN-166 (ibudilast).

The ALS Association and workplace learning company Schoox are partnering to offer education resources to providers, ...

Columnist Dagmar Munn explains how the use of a shoehorn not only helps her put on shoes, but also allows for some gentle ...

Brainstorm Cell Therapeutics is seeking FDA clearances to launch a Phase 3b clinical trial to test its NurOwn stem cell ...

Daily treatment with IPL344 for up to three years was safe and slowed ALS progression in a small Phase 2a clinical trial, ...

Neurosense Therapeutics’ PrimeC significantly reduces blood levels of miRNAs linked to amyotrophic lateral sclerosis, trial ...

TRE-515, a small molecule inhibitor of deoxycytidine kinase, is being developed for autoimmune diseases and in clinical ...

Verge Genomics will use digital biomarkers to assess short-term disease progression in an ALS trial testing its VRG50635 ...

RAG-17 therapy slowed functional decline and stabilized or improved breathing in people with ALS who carry mutations in the SOD1 gene.

Columnist Kristin Neva and her husband, Todd, make do with a backup wheelchair while a new one is on order and the old one is having trouble.

A rare mutation that leads to high CREB3 activity is associated with a reduced risk of developing ALS and slower disease ...